Abstracts tagged "Tumor necrosis factor (TNF)"

Abstract Number: 0884 • ACR Convergence 2020
Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Robert McLean², Taylor Blachley², Laura Anatale-Tardiff³, Christopher Saffore⁴, Patrick Zueger⁴ and Alexis Ogdie⁵, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴AbbVie Inc., North Chicago, IL, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is no single accepted measure of low/minimal disease activity (LDA/MDA) for patients with PsA; thus, describing the characteristics of real-world patients meeting different…
Abstract Number: 0967 • ACR Convergence 2020
Absence of Thy1 Associated with Severe Bone Loss in the TNF-transgenic (TNF-Tg) Mice Arthritis Model
Ananta Paine¹, Maria de la Luz Garcia-Hernandez², Marc Nuzzo³, Stacey Duemmel³, Benjamin Korman¹ and Christopher Ritchlin¹, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Department of Medicine, University of Rochester Medical Center, West Henrietta, NY, ³Department of Medicine, University of Rochester Medical Center, Rochester
Background/Purpose: Thy1 (CD90) is a glycosylated, glycophosphatidylinositol (GPI)-anchored membrane protein noted to be expressed on many cells including T lymphocytes, stem cells, osteoblasts and fibroblasts.…
Abstract Number: 0998 • ACR Convergence 2020
Differential Roles of TNFRI and TNFRII in the Morphology of Secondary Lymphoid Organs
Kim Jeucken¹, Jan Piet van Hamburg¹ and Sander Tas², ¹Amsterdam Rheumatology and Immunology Center (ARC), Department of Rheumatology and Clinical Immunology, Department of Experimental Immunology and Amsterdam Infection and Immunity Institute, Amsterdam UMC; location AMC, University of Amsterdam, Netherlands, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center (ARC), Department of Rheumatology and Clinical Immunology, Department of Experimental Immunology and Amsterdam Infection and Immunity Institute, Amsterdam UMC; location AMC, University of Amsterdam, Netherlands, Utrecht, Netherlands
Background/Purpose: Tumour necrosis factor (TNF) induced signaling events are important in lymphoid organ development and function, both in health and in immune-mediated inflammatory diseases such…
Abstract Number: 1366 • ACR Convergence 2020
Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation
Juergen Braun¹, Ricardo Blanco², Helena Marzo-Ortega³, Lianne Gensler⁴, Filip Van den Bosch⁵, Hideto Kameda⁶, Denis Poddubnyy⁷, Marleen van de Sande⁸, Anna Wiksten⁹, Brian Porter¹⁰, Santiago Moreno⁹, Abhijit Shete⁹, Hanno Richards⁹, Sibylle Haemmerle⁹ and Atul Deodhar¹¹, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany, ²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁴University of California San Francisco, San Francisco, CA, ⁵Ghent University Hospital, Ghent, Belgium, ⁶Toho University, Tokyo, Japan, ⁷Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Oregon Health & Science University, Portland, OR
Background/Purpose: Active non-radiographic axial spondyloarthritis (nr-axSpA) is often determined on the basis of objective signs of inflammation (elevated C-reactive protein [CRP] and/or evidence of sacroiliitis…
Abstract Number: 1497 • ACR Convergence 2020
COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance
Bonnie Bermas¹, Megan Clowse², Milena Gianfrancesco³, Jonathan Hausmann⁴, Pedro M Machado⁵, Emily Sirotich⁶, Helen Robinson⁷, Anja Strangfeld⁸, Jinoos Yazdany⁹ and Philip Robinson¹⁰, ¹UTSouthwestern.edu, Dallas, TX, ²Duke University, Chapel Hill, NC, ³University of California, San Francisco, San Francisco, CA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵University College London, London, United Kingdom, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Queensland School of Medicine, HERSTON, Queensland, Australia, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹UCSF, San Francisco, CA, ¹⁰University of Queensland, Herston, Queensland, Australia
Background/Purpose: The impact of COVID-19 on pregnancy in patients with rheumatic disease is unknown. We describe COVID-19 outcomes in pregnant rheumatic disease patients reported to…
Abstract Number: 1895 • ACR Convergence 2020
Radiographic Progression in Patients with Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)
Maria Llop¹, Mireia Moreno², Jordi Gratacós³, Victoria Navarro-Compán⁴, Eugenio De Miguel⁵, Pilar Font⁶, Teresa Clavaguera⁷, Luis Francisco Linares⁸, Beatriz Joven⁹ and Xavier Juanola¹⁰, ¹Hospital Universitari Parc Taulí I3PT, Sabadell, Catalonia, Spain, ²Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, ³University Hospital Parc Tauli Sabadell, Barcelona, Spain, ⁴Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁶Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁷Hospital Universitari Trueta, Girona, Spain, ⁸Hospital de la Arrixaca, Murcia, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Rheumatology Service, University Hospital Bellvitge, IDIBELL, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Clinical efficacy of TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA) has been widely probed in randomized control trials. In clinical practice, some studies suggested…
Abstract Number: 2022 • ACR Convergence 2020
Effects of Anti-TNF-therapy on Osteoblastic Activity in Ankylosing Spondylitis – Results from a Prospective Study Using PET-MRI of SIJ and Spine
Xenofon Baraliakos¹, Styliani Tsiami², Christoph Rischpler³, Nils-Martin Bruckmann⁴, Wolfgang Fendler³, Julian Kirchner⁵, Ken Herrmann³, Lino Morris Sawicki⁵ and Juergen Braun⁶, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Department of Nuclear Medicine, University Essen-Duisburg, Essen, Germany, ⁴Department of Radiology, University Duesseldorf, Düsseldorf, Germany, ⁵Department of Radiology, University Duesseldorf, Duesseldorf, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany
Background/Purpose: The clinical efficacy of TNFi in patients with axSpA is well established but its effect on new bone formation is still unclear. Positron emission…
Abstract Number: 94 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells
Shotaro kawano¹, Hiroki Mitoma ², Shoichiro Inokuchi ³, Masahiro Ayano ², Yasutaka Kimoto ⁴, Mitsuteru Akahoshi ², Yojiro Arinobu ², Koichi Akashi ², Takahiko Horiuchi ⁵ and Hiroaki Niiro ⁶, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Japan, ³Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Fukuoka, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁶Clinical Education Centre, Kyushu University Hospital, Fukuoka, Japan, Fukuoka, Japan
Background/Purpose: Tumor Necrosis Factor (TNF) α is a multifunctional cytokine with pro-inflammatory and anti-inflammatory characteristics. Regulatory T cells (Treg) express a remarkably high level of…
Abstract Number: 106 • 2019 ACR/ARP Annual Meeting
Increased T Cell Polyreactivity with Marked Accumulation of TNF-α DP (CD4+CD8+) in the Synovial Tissue of pre-RA, Arthralgia Subjects
Achilleas Floudas¹, Douglas Veale ² and Ursula Fearon ³, ¹Trinity Biomedical Sciences Institu, DUBLIN, Ireland, ²EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland, ³Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland
Background/Purpose: Effective treatment of Rheumatoid arthritis (RA) patients is achievable within a short window of opportunity following diagnosis. Identification of pathogenic immune mechanisms at a…
Abstract Number: 614 • 2019 ACR/ARP Annual Meeting
Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data
Bon San Koo¹, Yu-Cheol Lim ², Min-Young Lee ³, Ja-Young Jeon ⁴, Hyun-Jeong Yoo ⁵, In-Sun Oh ², Ju-Young Shin ² and Tae-Hwan Kim ⁶, ¹Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, ²School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea, ³VIAplus, Siheung, Republic of Korea, ⁴Pfizer Inc, Seoul, Republic of Korea, ⁵Pfizer Korea, Seoul, Republic of Korea, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Tapering of tumor necrosis factor (TNF) inhibitors may be considered in patients with ankylosing spondylitis (AS) with low disease activity. However, there is still…
Abstract Number: 752 • 2019 ACR/ARP Annual Meeting
Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis
Corrado Campochiaro¹, Alessandro Tomelleri ², Silvia Sartorelli ³, Giulio Cavalli ², De Luca Giacomo ⁴, Elena Baldissera ² and Lorenzo Dagna ², ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, ³Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ⁴Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Milan, Italy
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis affecting mainly young women. Biologic agents are currently use to treat refractory TA patients but no…
Abstract Number: 772 • 2019 ACR/ARP Annual Meeting
The Study of the Novel G87V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)
Shoko Tsuji¹, Hidenori Matsuzaki ², Masanori Iseki ³, Akiko Nagasu ¹, Hiroyasu Hirano ¹, Katsuhiko Ishihara ⁴, Naoyasu Ueda ⁵, Yoshitaka Honda ⁶, Takahiko Horiuchi ⁷, Ryuta Nishikomori ⁸, Yoshitaka Morita ¹ and Tomoyuki Mukai ⁹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Life Sciences, Faculty of Life and Environmental Sciences, Prefectural University of Hiroshima, shobara, Hiroshima, Japan, ³Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Immunology and Molecular Genetics, Kurashiki, Okayama, Japan, ⁵Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan, ⁶Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁷Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁸Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Fukuoka, Japan, ⁹Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Okayama, Japan
Background/Purpose: TNF Receptor-Associated Periodic Syndrome (TRAPS) is one of the autoinflammatory diseases. TRAPS is caused by heterozygous mutations in the TNFRSF1A gene. Although more than…
Abstract Number: 785 • 2019 ACR/ARP Annual Meeting
Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience
Muhammad Shipa¹, Anastasia-vasiliki Madenidou ², vera Choida ¹, Anna Radziszewska ³, corinne fisher ⁴, coziana ciurtin ¹, maria Leandro ¹ and Debajit Sen ¹, ¹Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, London, United Kingdom, ²Centre for Adolescent Rheumatology, University College London London, UK, LOndon, ³University College London, London, United Kingdom, ⁴Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, lonodn, United Kingdom
Background/Purpose: Biologics have transformed the treatment of Juvenile idiopathic arthritis (JIA) and escalation toTumour Necrosis Factor - α inhibitors (TNFi) after failure of methotrexate (MTX)…
Abstract Number: 929 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study
Stanley Cohen¹, Katie Tuckwell ², Rebecca Kunder ², Tamiko Katsumoto ³, Rui Zhao ², Alberto Berman ⁴, Nemanja Damjanov ⁵, Dmytro Fedkov ⁶, Slawomir Jeka ⁷ and Mark Genovese ³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Genentech, Inc., South San Francisco, CA, ³Stanford University, Stanford, CA, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, ⁶Bohomolets National Medical University, Kyiv, Ukraine, ⁷University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland
Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an orally administered, highly selective, non-covalent, and reversible small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK).1 We report the efficacy…
Abstract Number: 947 • 2019 ACR/ARP Annual Meeting
TNF Inhibitor Treatment and Dramatic Stroke Risk Reduction in Patients with Deficiency of Adenosine Deaminase 2
Ryan Laird¹, Patrycja Hoffmann ², Karyl Barron ², Deborah Stone ², Michele Nehrebecky ³, Anne Jones ², Tina Romeo ², Camilo Toro ³, Arianne Soldatos ⁴, Cornelia Cudrici ³, Daniel Kastner ² and Amanda Ombrello ², ¹National Institues of Health, Bethesda, ²National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, ⁴NIH/NINDS, Bethesda
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease caused by biallelic loss-of-function mutations in the ADA2 gene . Over 60 pathogenic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].